GeneHealth - Your precision medicine

Penile Cancer

Disease Details

Family Health Simplified

Buy Membership

Description: Penile cancer is a rare malignancy that occurs on the skin or in the tissues of the penis.
Type: Penile cancer is primarily classified as a malignant neoplasm of the penis, typically a type of squamous cell carcinoma. There is no known genetic transmission pattern for penile cancer, as it is generally not considered hereditary. It is more commonly associated with risk factors such as human papillomavirus (HPV) infection, smoking, poor hygiene, and phimosis.
Signs And Symptoms: Penile cancer can present as redness and irritation on the penis with a skin thickening on the glans or inner foreskin or an ulcerative, outward growing (exophytic) or “finger-like” (papillary) growth. Penile cancer may accompany penile discharge with or without difficulty or burning or tingling while urinating (dysuria) and bleeding from the penis.
Prognosis: Prognosis can range considerably for patients, depending where on the scale they have been staged. Generally speaking, the earlier the cancer is diagnosed, the better the prognosis. The overall 5-year survival rate for all stages of penile cancer is about 50%.
Onset: The onset of penile cancer typically occurs in men over the age of 50, although it can develop at any age. Early symptoms may include changes to the skin on the penis, such as a growth or sore that doesn't heal, changes in skin color, thickening, or a lump. Other signs can include foul-smelling discharge or bleeding. Early detection and treatment are crucial for better outcomes.
Prevalence: Penile cancer is considered rare, particularly in developed countries. The incidence rate varies by region but is generally less than 1 case per 100,000 males per year in Western countries. It is more common in some parts of Africa, Asia, and South America.
Epidemiology: Penile cancer is a rare cancer in developed nations, with annual incidence varying from 0.3 to 1 per 100,000 per year, accounting for around 0.4–0.6% of all malignancies. The annual incidence is approximately 1 in 100,000 men in the United States, 1 in 250,000 in Australia, and 0.82 per 100,000 in Denmark. In the United Kingdom, fewer than 500 men are diagnosed with penile cancer every year.In the developing world, penile cancer is much more common. For instance, in Paraguay, Uruguay, Uganda and Brazil the incidence is 4.2, 4.4, 2.8 and 1.5–3.7 per 100,000, respectively. In some South American countries, Africa, and Asia, this cancer type constitutes up to 10% of malignant diseases in men.As of 1997 the lifetime risk was estimated as 1 in 1,437 in the United States and 1 in 1,694 in Denmark.
Intractability: Penile cancer is not typically considered intractable. It can often be treated successfully, especially when diagnosed early. Treatment options include surgery, radiation therapy, and chemotherapy, depending on the stage and extent of the disease. Early detection and prompt treatment are crucial for a favorable outcome. However, advanced stages of penile cancer can be more difficult to treat effectively, and the prognosis may be poorer in such cases.
Disease Severity: Penile cancer is a rare type of cancer that occurs on the skin or in the tissues of the penis. The severity of penile cancer can vary widely depending on factors such as the stage at diagnosis and the grade of the cancer cells. Early-stage penile cancer, when detected and treated promptly, often has a good prognosis. Advanced stages, where the cancer has spread to other parts of the body, can be more challenging to treat and may have a poorer prognosis. Treatment options typically include surgery, radiation therapy, and sometimes chemotherapy, depending on the extent of the disease.
Healthcare Professionals: Disease Ontology ID - DOID:11615
Pathophysiology: Penile cancer typically originates in the epithelial cells of the glans or foreskin. The most common type is squamous cell carcinoma. Pathophysiologically, it often begins as a pre-cancerous lesion such as penile intraepithelial neoplasia (PIN), which can progress to invasive cancer. Human papillomavirus (HPV) infection, particularly types 16 and 18, is a significant risk factor, contributing to genetic mutations and oncogenic transformation. Chronic inflammation, poor hygiene, phimosis, and smoking are also associated with increased risk. The cancer can invade local structures and metastasize to regional lymph nodes, leading to systemic spread.
Carrier Status: Penile cancer does not involve a "carrier status" as it is not a genetically inherited condition. It typically develops due to various risk factors like human papillomavirus (HPV) infection, smoking, poor hygiene, and certain pre-existing conditions, but not due to carrying specific genetic traits.
Mechanism: Penile cancer typically originates in the squamous cells of the penis and is primarily driven by several molecular mechanisms. Human papillomavirus (HPV) infection, particularly with high-risk strains like HPV-16 and HPV-18, is a significant risk factor. The viral oncoproteins E6 and E7 interfere with tumor suppressor proteins p53 and Rb, respectively, leading to uncontrolled cell proliferation and inhibition of apoptosis.

Other molecular mechanisms involve genetic and epigenetic alterations. Mutations in oncogenes like PIK3CA and tumor suppressor genes such as TP53 are common. Epigenetic changes include DNA methylation and histone modification, which can result in the silencing of tumor suppressor genes and activation of oncogenes. Chronic inflammation and immune system evasion are also pivotal, often associated with poor penile hygiene and phimosis.

Collectively, these mechanisms contribute to the initiation and progression of penile cancer by promoting uncontrolled cell growth, resistance to apoptosis, genomic instability, and alterations in cell signaling pathways.
Treatment: Treatment of penile cancer will vary depending on the clinical stage of the tumor at the time of diagnosis. There are several treatment options for penile cancer, depending on staging. They include surgery, radiation therapy, chemotherapy, and biological therapy. The most common treatment is one of five types of surgery:

Wide local excision—the tumor and some surrounding healthy tissue are removed
Microsurgery—surgery performed with a microscope is used to remove the tumor and as little healthy tissue as possible
Laser surgery—laser light is used to burn or cut away cancerous cells
Circumcision—cancerous foreskin is removed
Amputation (penectomy)—a partial or total removal of the penis, and possibly the associated lymph nodes.The role of radiation therapy includes an organ-sparing approach for early-stage penile cancer at specialized centres. Furthermore, adjuvant therapy is used for patients with locally advanced disease or for symptom management.
Compassionate Use Treatment: Compassionate use treatment for penile cancer typically involves access to investigational drugs outside of clinical trials for patients with serious or life-threatening conditions who have no other treatment options. These might include targeted therapies, immunotherapies, or experimental drugs showing promise in early trials.

Off-label or experimental treatments for penile cancer might include:

1. **Checkpoint Inhibitors**: Immunotherapies like pembrolizumab (Keytruda) or nivolumab (Opdivo) that have shown effectiveness in other cancers might be considered.
2. **Targeted Therapies**: Drugs that target specific molecular pathways, such as EGFR inhibitors, might be used if the cancer expresses certain proteins.
3. **Chemotherapy Combinations**: Using unapproved combinations or doses of chemotherapy drugs tested in clinical trials.
4. **HPV Vaccines**: Investigating the use of HPV vaccines for therapeutic purposes in HPV-related penile cancers.
5. **Gene Therapy**: Experimental approaches looking at altering genetic material to treat or stop the progression of cancer.

These treatments are typically considered when standard treatments have failed, and they are usually administered as part of a clinical trial or special program.
Lifestyle Recommendations: For penile cancer, the following lifestyle recommendations can help reduce the risk or support treatment:

1. **Smoking Cessation**: Quit smoking, as smoking is a significant risk factor.
2. **Safe Sexual Practices**: Use protection to reduce the risk of human papillomavirus (HPV) infection, which is linked to penile cancer.
3. **HPV Vaccination**: Get vaccinated against HPV.
4. **Good Hygiene**: Maintain good genital hygiene, including regular cleaning of the foreskin for uncircumcised men.
5. **Healthy Diet**: Eat a balanced diet rich in fruits, vegetables, and whole grains to support overall health.
6. **Regular Medical Checkups**: Attend regular checkups for early detection and management of any health issues.

These actions can help mitigate risk factors associated with penile cancer.
Medication: There are no specific medications that can cure penile cancer. Treatment typically involves surgery, radiation therapy, and/or chemotherapy depending on the stage and extent of the cancer. For chemotherapy, drugs like cisplatin, 5-fluorouracil (5-FU), and paclitaxel are sometimes used. Each patient's treatment plan is tailored to their specific situation by their healthcare provider.
Repurposable Drugs: As of the latest insights, there are no widely recognized repurposable drugs specifically approved for penile cancer. Treatment typically involves surgery, radiation therapy, and chemotherapy. However, repurposing drugs used for other cancers, such as checkpoint inhibitors or tyrosine kinase inhibitors, is an area of ongoing research. Consultation with a specialist is crucial for updated and personalized treatment options.
Metabolites: Metabolites are small molecules involved in metabolism. In the context of penile cancer, certain metabolites may be altered due to cancerous activities. Metabolic profiling can identify these changes, potentially aiding in early diagnosis and understanding the disease's progression. Examples include alterations in amino acids, lipids, and nucleotides. However, specific biomarkers and their clinical utility require further research to establish standardized diagnostic or therapeutic protocols.
Nutraceuticals: Nutraceuticals, which include dietary supplements, functional foods, and herbal products, have not been well-studied specifically for penile cancer. The primary treatments for penile cancer include surgical interventions, radiation therapy, and chemotherapy. While some nutraceuticals may support general health or boost the immune system, their efficacy and safety for treating or preventing penile cancer are not established. Always consult with healthcare professionals before using any supplements or alternative treatments for cancer.
Peptides: Regarding penile cancer, peptides and nanotechnology are areas of ongoing research and development.

1. **Peptides**: These are short chains of amino acids that have potential uses in the treatment and diagnosis of various cancers, including penile cancer. Peptides can serve as biomarkers for cancer detection, targets for immunotherapy, or be developed as therapeutic agents that can disrupt cancer cell functions.

2. **Nanotechnology**: This involves the manipulation of matter at a molecular or atomic level, and it has promising applications in cancer treatment. For penile cancer, nanotechnology can be used to deliver drugs directly to tumor cells with high precision, thereby minimizing damage to surrounding healthy tissues. Nanoparticles can also be used for imaging to improve tumor detection and monitoring.

Both peptides and nanotechnology offer potential advancements in the treatment and management of penile cancer, although much of the work is still in experimental stages.